Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
Aura Biosciences (Nasdaq: AURA) launched an underwritten public offering of common stock and, for certain investors, pre-funded warrants to purchase common stock. Aura also intends to give underwriters a 30-day option to buy up to an additional 15% of the offering.
The offering is subject to market conditions and will be made from a Form S-3 shelf registration declared effective April 5, 2024; final terms will appear in a prospectus supplement filed with the SEC.
Positive
- Access to capital via an underwritten public offering
- Underwriter support from Leerink Partners, TD Cowen, and Evercore ISI
Negative
- Potential dilution to existing shareholders from new shares and pre-funded warrants
- Timing and size uncertainty as the offering is subject to market conditions
News Market Reaction – AURA
In the May 4 session, AURA gained 19.12%, reflecting a significant positive market reaction. Argus tracked a peak move of +43.7% during that session. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 3.5x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Offering pricing | Positive | +5.7% | Pricing of public offering expected to raise $75.0M in gross proceeds. |
| May 15 | Offering announced | Neutral | +5.7% | Announcement of proposed public offering of common stock and warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior offering-related announcements saw consistently positive price reactions of about 5.71%, suggesting past financings were received constructively.
Recent history shows Aura combining capital-raising with clinical progress. In May 2025, it announced a proposed offering followed the same day by a priced deal expected to raise $75.0M, both tagged as offerings and each linked to a 5.71% gain. Alongside, earnings and conference updates in late 2025 and early 2026 highlighted advancing Phase 3 and bladder cancer studies and cash of $144.2M funding operations into Q1 2027. Today’s proposed offering fits this pattern of financing alongside pipeline advancement.
Key Terms
pre-funded warrants financial
underwritten public offering financial
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Aura intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (
Leerink Partners, TD Cowen and Evercore ISI are acting as joint bookrunning managers for the offering. LifeSci Capital is also acting as a bookrunning manager in the offering. Citizens Capital Markets is acting as a co-manager for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 (333-278253) that was filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2024 and declared effective by the SEC on April 5, 2024. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
The final terms of the offering will be disclosed in a final prospectus supplement filed with the SEC.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Aura’s lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura is headquartered in Boston, MA. Aura’s mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
Forward-Looking Statements
Various statements in this release concerning the timing, structure and completion of the proposed public offering on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Aura’s control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Aura’s stock price, changes in market conditions, the final terms of the public offering and satisfaction of customary closing conditions related to the public offering, as well as those risks more fully discussed in the section entitled “Risk Factors” in the prospectus supplement and registration statement referenced above, Aura’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 30, 2026 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that Aura will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Aura undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
Investor and Media Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
Source: Aura Biosciences, Inc.
